Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab.

Obinutuzumab appears to be effective and steroid-sparing in renal and non-renal SLE patients with secondary non-response to rituximab. These patients have severe disease with few treatment options but given responsiveness to B cell depletion, switching to humanized type-2 anti-CD20 therapy is a logical approach.